Molbio Diagnostics IPO

Molbio Diagnostics Limited is a listed issue, offered in a price band of ₹807 to ₹807 per share, in lots of 18 shares. Every figure below is taken from the issue's own filings and exchange disclosures.

Issue details

Price band

₹807 – ₹807

Lot size

18 shares

Minimum investment

₹14,526

Issue size

₹939.7 Cr

Fresh issue

₹200 Cr

Offer for sale

₹739.7 Cr

Opens

10 Aug 2026

Closes

12 Aug 2026

Listing date

17 Aug 2026

Registrar

KFin Technologies Limited

Symbol

MOLBIO

One lot of 18 shares at the upper band price of ₹807 is ₹14,526 — the smallest retail application this issue accepts.

Lead managers: Kotak Mahindra Capital Company Limited.

Subscription status

How many times the issue has been applied for, by investor category, as reported by the exchange at 12 Aug 2026, 07:05 pm IST.

Grey market premium (GMP)

Latest reported GMP

₹120

Implied over upper band

14.90%

As of

17 Aug 2026, 07:05 pm IST

How the reported premium has moved. The trend matters more than any single reading — a premium that is drifting down into the close is a different signal from one holding firm.

Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.

Reported financials

As disclosed in the offer document. Figures in ₹ crore unless the filing states otherwise.

Strengths disclosed in the offer document

• The company is well-positioned to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
• The company has strong R&D capabilities and a track record of developing innovative diagnostic products.
• The company has developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
• The company has a scalable business model with strong entry barriers, a high proportion of recurring revenues, and a growing suite of tests.
• The company's strategic collaborations and acquisitions enhance its capabilities and offerings.
• The company has a management team with deep domain expertise and a track record of delivering strong financial performance.

Risk factors disclosed in the offer document

• The company derives a significant portion of its revenues from sales to Indian central and state governments and international aid agencies, making it vulnerable to unfavorable policy changes or decreased funding.
• A significant portion of the company's revenues is derived from the sale of diagnostic test kits for tuberculosis (TB), making it susceptible to declines in demand for these kits.
• The company relies on its top 10 customers for a significant portion of its revenue, and the loss of these customers or a decline in demand could adversely affect its business.
• The company's investments in R&D may not result in the successful development and government approval of new tests, which could adversely affect its business.
• The company incurred losses in Fiscal 2023 and may incur losses in the future.
• The company's sales cycle and sales demand are variable, making it difficult to forecast business results.
• The company's inability to accurately forecast demand for its products and manage its inventory may adversely affect its business.
• Product liability claims or regulatory actions could have an adverse effect on the company's business, financial condition, results of operations, and cash flows.

These are the company's own disclosures, not Alphave's assessment. Read the offer document →

What this page will not tell you

Whether to apply

Alphave is NISM-certified, not a SEBI-registered research analyst. There is no rating, verdict or recommendation on this issue anywhere on this page.

What it will list at

Nobody knows, and GMP is not a forecast of it. It is an unofficial over-the-counter quote reported by third parties, shown here with its source time so you can judge how stale it is.

Your allotment

Allotment is decided by the registrar (KFin Technologies Limited) after the issue closes. Track the whole calendar in the IPO Centre.

← All current and upcoming IPOs · Open the interactive Molbio Diagnostics terminal →